Data Includes Additional Analyses of Long-Term Extension Phase 1b Study With Titration Cohort at 36 Months and Fixed-Dose Cohorts at 48 Months. CAMBRIDGE, Mass., Aug. 28, 2018(Nasdaq: BIIB) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced results from a recent analysis….
Posted: 2018-08-28 13:53:00